Get the Stockscreener App
2.70
4.25%
0.11
After Hours:
2.67
-0.03
-1.11%
Anixa Biosciences Inc stock is traded at $2.70, with a volume of 131.60K.
It is up +4.25% in the last 24 hours and down -10.60% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$2.59
Open:
$2.64
24h Volume:
131.60K
Relative Volume:
0.77
Market Cap:
$90.53M
Revenue:
$210.00K
Net Income/Loss:
$-10.40M
P/E Ratio:
-8.5742
EPS:
-0.3149
Net Cash Flow:
$-6.88M
1W Performance:
-2.53%
1M Performance:
-10.60%
6M Performance:
-20.00%
1Y Performance:
-14.29%
1-Day Range:
$2.56
$2.83
1-Week Range:
$2.45
$2.89
52-Week Range:
$2.331
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.70 | 86.84M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Exclusive: Anixa Biosciences' ovarian cancer drug candidate shows longer survival with no major safety issues - MSN
Anixa Biosciences (NASDAQ:ANIX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress - MarketBeat
Can Anixa Biosciences Inc keep up with sector leadersTrade Risk Assessment & Verified Stock Trade Ideas - baoquankhu1.vn
Anixa Biosciences Featured on Water Tower Research Healthcare Ha - GuruFocus
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast - PR Newswire
Experimental breast cancer vaccine shows positive data, Anixa CEO says - Stock Titan
Anixa Biosciences Shareholders Back Board and Compensation - TipRanks
Anixa Biosciences (NASDAQ: ANIX) investors approve directors, pay and auditor - Stock Titan
Anixa Biosciences, Inc. (ANIX) Shareholder/Analyst CallSlideshow (NASDAQ:ANIX) 2026-03-11 - Seeking Alpha
Anixa Biosciences : 2026 Annual Meeting of Shareholders Presentation - marketscreener.com
Anixa Biosciences Inc. Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
Anixa receives Korean patent allowance for breast cancer vaccine By Investing.com - Investing.com Canada
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology - irw-press.com
Anixa Biosciences Inc reports results for the quarter ended January 31Earnings Summary - TradingView
ANIXA BIOSCIENCES ($ANIX) Releases Q1 2026 Earnings - Quiver Quantitative
Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Anixa 10-Q: $0 Revenue, $(0.08) EPS for Q3 (Jan 31, 2026) - TradingView
Anixa Biosciences (NASDAQ: ANIX) narrows loss and advances cancer vaccine and CAR-T programs - Stock Titan
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 - marketscreener.com
Anixa Biosciences Receives Notice of Allowance from Korean Minis - GuruFocus
Anixa Biosciences (ANIX) Secures Patent in South Korea for Breas - GuruFocus
Anixa receives Korean patent allowance for breast cancer vaccine - Investing.com
Anixa Biosciences (NASDAQ:ANIX) Upgraded to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX SEC FilingsAnixa Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ANIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - MarketBeat
Anixa Biosciences to host 2026 annual meeting of stockholders and provide corporate update highlighting recent clinical and regulatory progress - marketscreener.com
Anixa Biosciences To Host 2026 Annual Meeting Of Stockholders And Provide Corporate Update Highlighting Recent Clinical And Regulatory Progress - TradingView
Anixa to outline ovarian CAR-T survival, breast cancer vaccine data - Stock Titan
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Investing News Network
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote - GuruFocus
Co-inventor of Anixa cancer CAR-T to headline 2026 cell therapy retreat - Stock Titan
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic - Intellectia AI
Can Anixa Biosciences Inc. stock double in the next yearJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
ANIX: Robust 2025 Milestones Set the Stage for a Pivotal 2026 - Smartkarma
Anixa Biosciences to Present at the iAccess Alpha Virtual Best I - GuruFocus
Whale Trades: Will Anixa Biosciences Inc. stock reach all time highs in 2025 - mfd.ru
Breast cancer vaccine now in early clinical trials: What to know - abcnews.com
Will Anixa Biosciences Inc. stock reach all time highs in 20252025 Price Targets & Community Consensus Trade Alerts - mfd.ru
Why Anixa Biosciences Inc. stock is seen as undervalued2025 Fundamental Recap & Reliable Breakout Forecasts - mfd.ru
Anixa Biosciences Updates Ovarian Cancer CAR-T Trial Outcomes - Intellectia AI
Aug Momentum: Can Anixa Biosciences Inc maintain its current growth rate2025 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Anixa Biosciences Inc. keep up with sector leadersJuly 2025 Sentiment & Risk Managed Investment Entry Signals - mfd.ru
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance - MarketBeat
ANIX: Pivotal data from advanced cancer trials and fiscal discipline set the stage for a transformative 2026 - TradingView
Anixa reports promising survival data in ovarian cancer CAR-T trial - Investing.com Australia
Anixa Biosciences Reports Encouraging Patient Survival Observati - GuruFocus
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):